SecBot SecBot
SECBOTREPLAY Home › Report › SYRE

SYRE · Q3 net loss -$0.94 vs est -$0.84

Spyre Therapeutics, Inc. · PRESS-RELEASE filed Nov 3, 2026 at 16:01 ET

At the news

BEARISHIMPACT 5/10

PRESS-RELEASE filed Nov 3, 2026 at 16:01 ET

Spyre Therapeutics reported Q3 2026 net loss of $96.1M ($0.94 per common share), wider than the $11.2M loss a year ago, driven by increased R&D spending. The company highlighted positive Phase 2 data for its IBD pipeline and plans to advance TL1A programs into pivotal HS studies, with $1.47B pro forma cash providing runway into H2 2029. The EPS of -$0.94 is below the consensus estimate of -$0.84, representing a miss.

  • Q3 2026 net loss of $96.1M vs $11.2M in Q3 2025
  • EPS of -$0.94 per common share vs consensus -$0.84
  • R&D expenses rose to $89.2M from $45.2M YoY
  • Pro forma cash $1.47B with runway into H2 2029

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access